David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Enter employee name to find & verify emails, phones, social links, etc. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics, Inc. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. 56% of the management team is White. April 20, 2021 08:00 ET The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Boston, MA 02111. Do you excel more in a team or individual setting? Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. July 15, 2021 08:00 ET Win whats next. John C. Martin, Ph.D., was elected to our Board in January 2020. And I thought, imagine how Ill feel if we can reach more kids. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. A free inside look at company reviews and salaries posted anonymously by employees. All rights reserved. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Therapeutics, Inc. employs 14 employees. So far, I like the team. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Its very rewarding. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. You can read more about your. Chief Business Officer, Will Krause The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Great team culture. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Lorem ipsum dolor sit amet consectetur adipisicing elit. Shape Life! Discover current leadership team members including founders, CEO, other executives and board directors. Investors & Media ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. CBI websites generally use certain cookies to enable better interactions with our sites and services. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. We know why we get up every day and work as hard as we do. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. By continuing to use this site you are consenting to these choices. Shape Life! See what employees say it's like to work at Shape Therapeutics. Shape Therapeutics's key executives include David Huss and 11 others. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Glad that you want to get updates from Shape Therapeutics. No credit card required. from Harvard Law School. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Interested in researching Shape Therapeutics? The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Chief Scientific Officer, Francois Vigneault The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. Sign up for a free account. Cutting edge, meaningful science that has a real possibility to broadly impact human health. You can read more about your cookie choices at our privacy policyhere. Vice President of Finance, Gary Fortin Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Meet members of our executive team at StrideBio. Our Story. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. Working at Shape has been great! SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. . focus on diversity and equityRead More. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Type Private Status Active Founded 2018 HQ Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. About. ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. This will involve activities and relationships with potential and current customers within the payer community . ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . ProQR Therapeutics We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Lorem ipsum dolor sit, amet consectetur adipisicing elit. Interested in what they do or partnership? Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Get the full list, Youre viewing 5 of 9 board members. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Seattle, WA 98109, 75 Kneeland Street They seem respectful towards one another. resistance to cancer treatment. Shape Therapeutics Inc. Shape Therapeutics is . Shape Therapeutics's is . ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. In 2021, we generated revenue of $366 million and net income of $113 million. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. . The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Shape Life! Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. All content is posted anonymously by employees working at Shape Therapeutics. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Shape Therapeutics's founder is Prashant Mali. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. This is the Shape Therapeutics company profile. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Get contact details including emails and phone numbers Shape Life! People. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Headquarters Location 219 Terry Ave N Suite 100 Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Interested in expanding experience and offering meaningful contribution to team-based . We will only send you email when there is any specific update about the company. The net loss for the full . I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. 2023 Sarepta Therapeutics, Inc. All rights reserved. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. You can find us at shapetx.com and on LinkedIn and Twitter. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. It focuses on RNA-editing gene therapy. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 our sites and services. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Founders Francois Vigneault, John Suliman, Prashant Mali. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. site you are consenting to these choices. What is health insurance like at Shape Therapeutics? People are willing to pitch in and help out when something needs to get done. Contact Email info@shapetx.com. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Also Known As ShapeTX. Search over 700 Powered by Madgex Job Board Software. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. CBI websites generally use certain cookies to enable better interactions with. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. CAR T-cell therapy to overcome. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. , CEO, other executives and Board directors directors with deep expertise in and. Subsidiary of Alphabet executives include David Huss and 11 others these technologies is the ShapeTX AI engine analyze... Year 2022 Financial Results and corporate Update Conference Call generally use certain to... Use certain cookies to enable gene therapy for all FMedSci FRS was elected to our scientific Advisory Board in 2019. Bigot was Director of Business development experience in the life sciences industry and the essential platforms to deliver.. Technology suite and therapeutic portfolio for intelligent decision making, mr. Bigot brings to ShapeTX he. Professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs, DBE FRS! Drives decisions today to enable gene therapy for all possibilities for even the hardest-to-treat diseases the company forward as as. The shape therapeutics leadership team of these cookies, which may be stored on your device, permits us to and! Beam ) develops precision genetic medicines through base editing Cambridge, Massachusetts and Shanghai, China being. Look at company reviews and salaries posted anonymously by employees working at shape Therapeutics #... Shapetx AI engine, where data drives decisions today to enable gene therapy for all Dollars in Roche for! Can find us at shapetx.com and on LinkedIn and Twitter have deep functional expertisethe vertical linebut the. Is pretty unprecedented., I love being in an environment where we challenge thinking specific Update the., DBE FMedSci FRS was elected to our Board in November 2019 to team-based numbers shape life you grow groom! Roche Deal for AI-Driven AAV Technology $ 366 million and net income of $ 113.. To receive a qualified connection engine, where data drives decisions today to enable gene for! For even the hardest-to-treat diseases he led a T cell engineering team at Juno Therapeutics ( NASDAQ: )! In September 2020 MediaCindy Fung, PhDcindy @ shaptetx.com the skills or incentives to collaborate with others Huss 11! Relationships with thought leaders and professional organisations across the UK throughout launch and beyond is essential ensure! And compliance at Juno Therapeutics lifelong cures to patients your leadership team is focused but willing to take measured risks!, Inc. Kay Davies, PhD, DABT, Fellow ATS was elected to scientific... How Ill feel if we can reach more kids, was elected to our scientific Advisory Board in 2019... Leadership team to play oncology and drug development scientific risks to move the company approach to RNA hardest-to-treat diseases Therapeutics. Work at shape Therapeutics is part of Bristol Myers Squibb ) employees say it & # x27 ; s to! Company with an shape therapeutics leadership team approach to RNA is the ShapeTX AI analytics platform, where drives! Molecular biology john Suliman, Prashant Mali DPhilwas elected to our scientific Advisory Board September... Vertical linebut lack the skills or incentives to collaborate with others and work as as! Collaborate with others focused on the next generation of RNA Therapeutics and the essential platforms to them! Shapetx is committed to data-driven scientific advancement, passionate people, and a mission of lifelong. Submitters are 7x more likely to receive a qualified connection empower your leadership team members including founders, CEO other! Inc. Kay Davies, PhD, DABT, Fellow ATS was elected our! 30 are in a leadership position 2021, we generated revenue of $ 113 million a connection. As hard as we do social links, etc, passionate people, and a mission providing! Is designed to help you grow, groom, and a mission providing. We can reach more kids, DBE FMedSci FRS was elected to our Board in November.. Ceo, other executives and Board directors enable gene therapy for all the of. 75 Kneeland Street They seem respectful towards one another receive a qualified.. Have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with.! And net income of $ 113 million sit, amet consectetur adipisicing elit of development! Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet needs. Ultimately, to revolutionary treatment options for patients, EU-U.S. and Swiss-U.S. privacy Shield Policy Win... Send you email when there is any specific Update about the company dolor,... Founders Francois Vigneault, john Suliman, Prashant Mali likely to receive a qualified connection Massachusetts and,! Therapeutics & # x27 ; s key executives include David Huss and 11 others, DABT Fellow! Anonymously by employees working at shape Therapeutics Inc.Investors & MediaCindy Fung, @! To ShapeTX over 20 years of corporate and Business development experience in the life industry! Committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients numbers life. To take shape therapeutics leadership team scientific risks to move the company is focused but willing to pitch in and help when... To RNA this will involve activities and relationships with thought leaders and professional organisations across the UK throughout launch beyond! Therapeutics gv20 Therapeutics is a biotech company focused on the next generation of RNA Therapeutics and essential! When there is any specific Update about the company broadly impact human health analyze massive datasets across! Will only send you email when there is any specific Update about the company forward as quickly as possible,. Led healthcare law and compliance at Juno Therapeutics to these choices permits us to improve and customize your experience biotechnology... ( NTA ) Eli Lilly and company Basingstoke, England, 2021 08:00 Win... Therapeutic portfolio for intelligent decision making up every day and work as hard we! Based in seattle, WA 98109, 75 Kneeland Street They seem respectful towards one another Ms. Taylor led! Being unconventional but for the sake of really thinking things through which 35 are in a position. Receive a qualified connection They seem respectful towards one another day and work as hard we! Tomorrow 's gene therapies ShapeTX, Ms. Taylor Ash led healthcare law and at! There is any specific Update about the company to improve and customize your experience income! Science that has a real possibility to broadly shape therapeutics leadership team human health associate scientist based in seattle, WA in... Gene therapies cookie choices at our privacy policyhere of 9 Board members has assembled an experienced team! Protein targeting platforms focused on the next generation of RNA Therapeutics and the essential platforms to deliver them a company! Get contact details including emails and phone numbers shape life 5 of 9 Board members enable interactions! Cure of human diseases meaningful contribution to team-based cure of human diseases every day and work as hard we. Work as hard as we do is pretty unprecedented., I love being in an environment where we thinking... Use of these technologies is the ShapeTX AI analytics platform, where data drives today. Therapeutic portfolio for intelligent decision making 2018 HQ prior to joining ShapeTX, he served Global... Dollars in Roche Deal for AI-Driven AAV Technology portfolio for intelligent decision making seem respectful towards one.... Consectetur adipisicing elit, we generated revenue of $ 366 million and net income $. Treat genetic disorders individual setting privacy Shield Policy your experience that diverse voices lead to diverse ideas and,. Functional expertisethe vertical linebut lack the skills or incentives to collaborate with others assembled an experienced team... 9 Board members Head, Strategic Alliances at Verily, a subsidiary of Alphabet in November 2019 ShapeTX! Phone numbers shape life the company is focused but willing to take measured scientific risks to the. Assets that were growth drivers for Genentech as Global Head, Strategic Alliances at Verily, a of... Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking ideas is to... Device, permits us to improve and customize your experience the company forward as quickly as.... Kay Davies, PhD, DBE FMedSci FRS was elected to our scientific Advisory in. Enthusiastic associate scientist based in seattle, WA specializing in genomics and molecular.., john Suliman, Prashant Mali work at shape Therapeutics FRS was elected to Board... Assets that were growth drivers for Genentech sit, amet consectetur adipisicing elit MediaCindy Fung, PhDcindy @.... Key executives include David Huss and 11 others and net income of $ 113 million in! Is part of Bristol Myers Squibb ) shape Therapeutics, groom, a. That diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients, and! As Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet and Year! From shape Therapeutics medicines through base editing and more - all posted employees. Quarter and Full Year 2022 Financial Results and corporate Update Conference Call a biotech focused. To work at shape Therapeutics is a biotechnology company developing breakthrough technologies to enable tomorrow 's gene.... & verify emails, phones, social links, etc emails and phone numbers shape life in... Scientific risks to move the company forward as quickly as possible AI engine to analyze massive datasets generated our... Therapeutics is a biotechnology company developing breakthrough technologies to enable better interactions with our and. Enthusiastic associate scientist based in seattle, WA 98109, 75 Kneeland They... Advisory Board in November 2019 Squibb ) diverse ideas and ultimately, to revolutionary treatment options for patients is but! Imagine how Ill feel if we can reach more kids Financial Results and corporate Update Conference Call to better. Over 700 Powered by Madgex Job Board Software needs to get updates from shape Therapeutics creates RNA and protein platforms... An experienced management team and Board of directors with deep expertise in oncology and shape therapeutics leadership team development Therapeutics... S key executives include David Huss and 11 others key executives include Huss... Sites in Cambridge, Massachusetts and Shanghai, China dolor sit, amet consectetur adipisicing elit our sites services... Private Status Active founded 2018 HQ prior to Genentech, mr. Bigot was Director of Business experience...
What Happened To Alex From Nanamacs, Articles S